U.S. MEIBOMIAN GLAND DYSFUNCTION MARKET ANALYSIS

U.S. Meibomian Gland Dysfunction MarketSize and Trends

The U.S. Meibomian Gland Dysfunction market is estimated to be valued at US$ 3,037.5 million in 2023 and is expected to exhibit a CAGR of 15.6% during the forecast period (2023-2030).

Figure 1. U.S. Meibomian Gland Dysfunction Market Share (%), By Drug Type, 2023

U.S. Meibomian Gland Dysfunction Market – Driver

• Increasing prevalence of meibomian gland dysfunction syndrome: Increasing prevalence of meibomian gland dysfunction syndrome is expected to propel the growth of the U.S. meibomian gland dysfunctions market over the forecast period. For instance, according to a study published by the American Optometric Association in 2021, more than 16 million Americans, including twice as many women than men, were suffering from dry eye disease, and out of them around 70% of patients had meibomian gland disease. Moreover, according to the Fellow of the American College of Surgeons in January 2020, meibomian gland disease (also referred to as evaporative dry eye), is one of the most common causes of dry eyes across the globe. An estimated 50 to 70% of the elderly population has some degree of dry eye and nearly 70% of dry eye involves at least some degree of meibomian gland disease.
• Increasing excess usage of computers and mobile screens: The increasing excess usage of computers and mobile screens is expected to increase the incidence of meibomian gland dysfunction over the period of time and is also expected to aid in the growth of the market. People who frequently use computers or video screens are at high risk of developing meibomian gland dysfunction, as using screens for a long duration can lead to reduced blinking and tear production. Digital device usage has increased significantly in recent years among all age groups, due to extensive use for social and professional purposes. For instance, an article published in the National Library of Medicine Journal in March 2020, reported blue light emitted by digital screens can lead to symptoms of dry eyes which cause meibomian gland dysfunction. Exposure to blue light (range of 400–500 nm) can be harmful to the retina. Longer duration and less intense light exposure can also induce photochemical damage in the eyes.

Figure 2. . U.S. Meibomian Gland Dysfunction Market Share (%), By Distribution Channel, 2023

U.S. Meibomian Gland Dysfunction Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the U.S. Meibomian Gland Dysfunction market. During the lockdown, people's screen time (irrespective of their age) increased significantly, which had a severe impact, and an increase in ophthalmic disorders was observed. For instance, a research study published in December 2021 stated that both dry eye disease (DED) patients and healthy participants up to the age of 60 experienced worsening dry-eye symptoms during the COVID-19 lockout due to increased visual display terminal (VDT) period. The study also reported that younger persons had more severe dry-eye problems than older respondents, particularly during the lockdown. Therefore, the market gained traction as the restrictions were lifted. Since the pandemic led to an increase in dry eye disease cases globally. Hence, it is expected to propel the market growth during the forecast period.

U.S. Meibomian Gland Dysfunction Market Segmentation:

The U.S. meibomian gland dysfunction market report is segmented into Drug Type, By Route of Administration, and By Distribution Channel

• By Drug Type, the market is segmented into Cyclosporine, Omega-3 supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), and HY02–Minocycline Out of which, the Cyclosporine segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market during the forecast period and this is attributed to the increasing awareness of meibomian gland dysfunctions.
• By Route of Administration, the market is segmented into Oral and Topical. Out of which, the Oral segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market during the forecast period and this is attributed to increasing prevalence of meibomian gland dysfunctions.
• By Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Out of which, the Hospital Pharmacies segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market during the forecast period and this is attributed to the increasing prevalence of meibomian gland dysfunctions.